BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders

NEXT STORY
Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1×1 Day
PREV STORY
PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune®-Based COVID-19 Vaccine with an Award of up to Approximately US$60 million

author_avatar
NASDAQ Market News

Adaptive Biotechnologies Reports First Quarter 2021 Financial Results

author_avatar
NASDAQ Market News

Philips, BioIntelliSense and University of Colorado receive U.S. Department of Defense funding for early COVID-19 detection

author_avatar
NASDAQ Market News